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Measurement of von Willebrand factor antigen (VWF :Ag) levels is usually performed in a specialised laboratory which limits
its application in routine clinical practice. So far, no commercial rapid test kit is available for VWF :Ag estimation. This paper
discusses the technical aspect of latex agglutinationmethod which was established to suit the purpose of estimating vonWillebrand
factor (VWF) levels in the plasma sample. The latex agglutination test can be performed qualitatively and semiquantitatively.
Reproducibility, stability, linearity, limit of detection, interference, and method comparison studies were conducted to evaluate the
performance of this test. Semiquantitative latex agglutination test was strongly correlated with the reference immunoturbidimetric
assay (Spearman’s rho = 0.946, 𝑃 < 0.001, 𝑛 = 132). A substantial agreement (𝜅 = 0.77) was found between qualitative latex
agglutination test and the reference assay. Using the scoring system for the rapid latex test, no agglutination is with 0% VWF :Ag
(control negative), 1+ reaction is equivalent to <20% VWF :Ag, and 4+ reaction indicates >150% VWF :Ag (when comparing with
immunoturbidimetric assay). The findings from evaluation studies suggest that latex agglutination method is suitable to be used
as a rapid test kit for the estimation of VWF :Ag levels in various clinical conditions associated with high levels and low levels of
VWF :Ag.
1. Introduction
von Willebrand factor (VWF), a multimeric glycoprotein
produced by endothelial cells and megakaryocytes, plays
important roles in platelet adhesion at the sites of vascular
injury and in the coagulation process through stabilization
of factor VIII [1–3]. VWF was first identified in hereditary
bleeding disorder known as von Willebrand disease (VWD)
and later it has been associated with other clinical conditions
such as cancers, clotting, and vascular and liver disorders.
Quantitative and functional impairment of VWF may lead
to bleeding disorder. In contrast, elevated levels of VWF pre-
dispose to thrombotic complications [2, 3]. Epidemiological
studies have revealed that an increased level of VWF is sig-
nificantly associated with cardiovascular diseases and acute
vascular events [4–8], making it a potential biomarker in
disease progression and prognosis [9–11]. Cardiovascular dis-
ease is a global health problem and is a leading cause of death
in developed countries [12]. In developing countries, cardio-
vascular disease has become increasingly prevalent [12, 13].
Currently, the available test for measurement of VWF
level in plasma is VWF antigen (VWF :Ag) assay that is
usually performed by enzyme-linked immunosorbent assay
(ELISA) and automated immunoturbidimetric procedure
such as latex-immunoassay (LIA), which requires sophisti-
cated instrumentation andwell-trained laboratory personnel.
Furthermore, ELISA test is unsuitable for urgent testing [14,
15]. Despite the advanced technology of testing VWF levels
in a fully equipped laboratory, very little attention has been
focused on testing the VWF levels in areas with limited
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laboratory facilities or at the bedside. Thus, the application
of rapid, simple, and less expensive test method for the
detection of VWF might help in improving clinical manage-
ment in resource-limited setting. In the future, estimation
of VWF :Ag could be possible as a point of care testing in
clinical practice routinely.
Latex agglutination test has been the method of choice in
the development of a rapid test kit in many fields including
clinical and veterinary medicines [16–20]. In principle, latex
agglutination test is based on agglutination reactions between
antigen and antibody. Submicron microspheres or often
called “latex beads” are used as a solid support for the anti-
body (or antigen) to be adsorbed onto them. The latex beads
with adsorbed antibody (or antigen) are used to detect anti-
gen (or antibody) present in biological samples. Polystyrene
latex beads are commonly used in the latex agglutination
test because of their strong hydrophobic characteristic that
is ideal for the adsorption of materials such as proteins by a
simple passive adsorption method [21].
The use of latex beads was first described for the detection
of rheumatoid factor by Plotz and Singer in 1956 [22]. Since
then, latex tests have been developed to detect specific infec-
tious diseases, autoimmune diseases, hormones, drugs, and
serum proteins. The original method for attachment of pro-
teins (antibody) to latex beadswas passive adsorption. Passive
adsorption using plain polystyrene latex beads has been used
in the development of many latex tests for the detection of
antibody or antigen such as Group D salmonellae [23], CRP
[24], lactoferrin [25], and rotavirus [26]. Covalent coupling
method using functionalized latex beads such as carboxylated
polystyrene latex beads can produce more stabilized protein-
latex complex compared to passive adsorption method. It
has then become a method of choice in the development of
latex tests such as for the detection of anti-cysticercus anti-
bodies [27], IgM quantification in cerebrospinal fluid [28],
and detection of avian influenza virus subtype H5N1 [29].
Although covalent coupling methods have many advantages,
the passive adsorption method is still widely used until today
because of its simplicity and flexibility.
Conventional latex agglutination is not a new method,
but its application is limited in the field of hematology and
hemostasis.The latexmethod hasmoved towards automation
and currently the antigenic detection has been made easy
and specific with this new technology especially using the
monoclonal generated antibodies. However, the conventional
method may be useful to be applied as a rapid or screening
test before running the usual laboratory investigations. The
present study may provide evidence on the usage of a latex
agglutination test for the detection of VWF :Ag in the plasma
sample that could be commercialized in the future. In this
study, surfactant-free latex beads were selected in order to
avoid a variation in protein attachment condition that might
occur due to the variation in the surfactant purity.The aggre-
gation in the latex beads is prevented by the electrical charge
that is built onto the surface of the latex beads during their
synthesis. Chloromethyl latex beads have been selected to be
used in the passive adsorptionmethod.The beads have a high
density of chloromethyl groups attached to the styrenemono-
meric unit, and these functional groups can react directly
with amino groups in antibodies.The beads are of hydropho-
bic type and can be used at both high and low pH conditions.
The beads are stabilized by negatively charged sulfate groups
that provide the colloid stability. In terms of ease of washing
and suitability in simple visible test, latex beads with a size of
1 𝜇m were used.
This study was conducted with the aims to develop
and validate a latex agglutination test for the detection of
VWF :Ag. Method validation is a process to demonstrate
the suitability of the test method for its intended purpose.
Method validation is performed to determine the perform-
ance characteristics of the test method, for example, repro-
ducibility, stability, linearity, limit of detection, and compari-
son ofmethod, and also to estimate certain types of analytical
errors by performing interference study. Reproducibility
study estimates imprecision, stability study determines sta-
bility of the sample and reagent, linearity study determines
reportable range, detection limit study determines the lowest
concentration of analyte, method comparison estimates inac-
curacy, and interference study estimates error caused by other
materials that may be present in the specimen.
2. Materials and Methods
2.1. Sample Collection and Plasma Preparation. The study
protocol was approved by the Human Research Ethics
Committee from Universiti Sains Malaysia, Health Cam-
pus, Kubang Kerian, Kelantan, Malaysia [reference number:
USMKK/PPP/JEPeM253.3.(4)]. Blood samples for validation
studies were collected into 3.2% buffered trisodium citrate
(Becton Dickinson and Co., Plymouth, UK), and platelet-
poor plasma was prepared by centrifuging the blood at
2,500 g for 15 minutes at room temperature. Following cen-
trifugation, the top 2/3 of the plasma layer was transferred
into a plastic tube. The collected plasma was recentrifuged at
2,500 g for 15 minutes to remove any remaining red cells or
platelets. After centrifugation, the top 2/3 portion of plasma
volume was transferred into cryogenic vials, and the plasma
samples were frozen at −70∘C until use. On the day of
testing, plasma samples were thawed at 37∘C for 10 minutes
and mixed by gentle inversion prior to analysis, which was
performed within two hours after thawing.
2.2. Preparation of VWF Antibody-Latex Reagent. Chloro-
methyl latex beads, 1.0𝜇m in diameter, were purchased from
Life Technologies, USA. Prior to use, the latex beads were
washed according to the manufacturer’s instructions with
some modifications. Briefly, 2.5mL of 4% latex suspen-
sion was washed twice in 10mL imidazole buffer, pH 7.4
(120mMNaCl, 20mM imidazole, and 5mM citric acid) by
centrifuging the latex suspension at 3,000 g for 20 minutes
at room temperature. The final pellet was resuspended with
5mL imidazole buffer to obtain a suspension of 2%.
VWF antibody-latex reagent was prepared by passive
adsorption method according to the manufacturer’s protocol
and themethod described byMina et al., 2012 [30], with some
modifications. Briefly, 1.0mL of 2% latex suspension was cen-
trifuged at 3,000 g for 20 minutes at room temperature, and
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Table 1: Test score for qualitative latex agglutination test for VWF :Ag.
Test score Size of the agglutinated beads Appearance of the background Rapidity of the agglutination
1+ Small clumps Cloudy >2min
2+ Small clumps Cloudy >1min
3+ Small/large clumps Clear >30 sec
4+ Large clumps Clear <30 sec
VWF :Ag: von Willebrand factor antigen.
the supernatant was discarded. The pellet was resuspended
with 1mL phosphate-buffered saline, pH 7.4 (135mMNaCl,
2.6mMKCl, 8mMNa
2
HPO
4
, and 1.5mMKH
2
PO
4
), that
was added with 200𝜇L of polyclonal rabbit anti-human von
Willebrand Factor from Dako Denmark (3.1 g/L). The mix-
ture was incubated with gentle mixing on a horizontal rotator
(Barnstead Thermolyne Labquake Rotator, USA) at room
temperature for 24 hours. After incubation, the mixture was
centrifuged, and the supernatant was kept for determination
of unadsorbed antibody by BCA method using Micro BCA
Protein Determination Kit from Pierce Biotechnology, USA.
The concentration of unadsorbed antibody in the supernatant
was determined according to themanufacturer’s instructions.
The concentration of adsorbed antibody was estimated as the
difference between the initial concentration of antibody (i.e.,
620𝜇g) and the concentration of unadsorbed antibody in the
supernatant.
Thepellet was thenwashed twice in 4mL imidazole buffer
by centrifugation as stated earlier and resuspended with 3mL
imidazole buffer containing 1% bovine serum albumin
(Sigma-Aldrich, USA). The mixture was incubated with gen-
tle mixing at room temperature for one hour. After incuba-
tion, the mixture was centrifuged, and the pellet was washed
twice in 4mL imidazole buffer by centrifugation as stated
earlier. The final pellet was resuspended with 2mL imidazole
buffer containing 0.1% bovine serum albumin to obtain a
suspension of 1%, and the suspension was stored at 4∘C until
use.
The process described was carried out using different
concentrations of the VWF antibody to determine the appro-
priate concentration of antibody for the adsorption proce-
dure. As a control reagent, the process was conductedwithout
the antibody. All reagents were tested on known negative
and positive samples. Normal saline and buffers were used
as negative samples while commercial controls were used as
positive samples.
2.3. Latex Agglutination Test Procedure and Result Interpre-
tation. VWF antibody-latex reagent was brought to room
temperature and mixed gently before use. The sedimentation
of latex beads can occur during storage that can be reversed
by pipetting the suspension of latex beads through a fine tip
pipette until they are returned to a uniform suspension. Latex
agglutination test for the detection of VWF in a plasma sam-
ple was performed on a slide card (Thermo Scientific, UK).
Using a wooden applicator stick, 20 𝜇L of VWF antibody-
latex reagent was mixed with 20𝜇L of plasma sample on a
black reaction zone of the card. The card was rotated on
Figure 1: Positive (number 5) and negative (number 6) reactions of
qualitative latex agglutination test for VWF :Ag.
a horizontal shaker (Boekel GrantMicroplate Shaker, UK) for
threeminutes. After threeminutes, the agglutination reaction
was observed by visual inspection macroscopically with a
naked eye.
The detection and estimation of VWF by latex agglutina-
tion test can be performed using a qualitative test and semi-
quantitative test, respectively. Qualitative test was performed
on undiluted plasma sample, and the result was reported
as negative or positive. Invisible or hardly visible agglutina-
tion was reported as negative and visible agglutination was
reported as positive (Figure 1). For a positive result, the degree
of agglutination was scored from 1+ to 4+ based on the size
of the agglutinated beads, the appearance of the background,
and the rapidity of the agglutination development as shown
in Table 1. Semiquantitative test was performed on diluted
plasma sample. A positive plasma sample was serially diluted
twofold with normal saline. The highest dilution that still
shows a positive reaction is the end-titre of a sample.
2.4. Validation Studies on VWF Antibody-Latex Reagent
2.4.1. Reproducibility Study. Reproducibility studies were
performedwithin a day and between days.Within-day repro-
ducibility study was carried out by testing VWF antibody-
latex reagent on three plasma samples, and the end-titre
of each sample was determined three times. Between-day
reproducibility study was conducted by testing the reagent
in duplicate on two plasma samples, and the end-titre of the
samples was determined on days 1, 7, 14, and 21. The reagents
were also tested on low and normal controls from Instrumen-
tation Laboratories, Italy (Hemosil Special Test Control Level
2 and Hemosil Normal Control Assayed, resp.), on days 2, 4,
5, 7, 30, and 50.
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2.4.2. Stability Study. Stability of the reagent was checked
during storage of VWF antibody-latex reagent at 4∘C for 21
days. Qualitative test was performed on two plasma samples
on days 1, 2, 3, 4, 5, 6, 7, 14, and 21 using aliquots of samples
that were stored at −70∘C. A new aliquot of sample was used
in each experiment. Stability of plasma sample during storage
was also checked by testing VWF antibody-latex reagent
(stored at 4∘C) on aliquots of plasma samples which was
stored at 4∘C. After 0 (within two hours after blood collec-
tion), 1, 2, 3, 4, 5, 6, 7, 14, and 21 days, the qualitative test was
performed. The reagents were also tested on Hemosil Special
Test Control Level 2 and Hemosil Normal Control Assayed
(Instrumentation Laboratories, Italy). Semiquantitative latex
agglutination test was performed on these controls for up to
50 days. Batch to batch variation was tested with the reagents
prepared on two different dates, using two different lots of the
VWF antibody.
2.4.3. Linearity Study. The linearity of latex agglutination
test was determined by testing VWF antibody-latex reagent
on two patient samples which were serially diluted twofold.
The VWF :Ag level in diluted samples was measured by
immunoturbidimetric assay using Hemosil von Willebrand
Factor Antigen kit (Instrumentation Laboratory, Italy). Semi-
quantitative latex agglutination test was performed on
diluted samples, and the end-titres were compared with the
VWF :Ag levels. Graphical presentations of the semiquan-
titative VWF :Ag by latex agglutination test (𝑌) versus the
VWF :Ag by immunoturbidimetric assay (𝑋) were made for
individual sample and also for a combination of the two
samples.
2.4.4. Determination of Limit of Detection. Limit of detection
of latex agglutination test was determined by testing VWF
antibody-latex reagent on low-level samples (cryosuper-
natant). Seven cryosupernatant samples were serially diluted
twofold, and the VWF :Ag levels in the samples (neat) were
measured by immunoturbidimetric assay using Hemosil von
Willebrand Factor Antigen kit (Instrumentation Laboratory,
Italy). VWF :Ag levels in 1 : 2, 1 : 4, and 1 : 8 diluted samples
were estimated by dividing the VWF :Ag levels of neat sam-
ples by the dilution factors of 2, 4, and 8, respectively. Latex
agglutination test was performed to determine the lowest
level of VWF :Ag that shows positive agglutination reaction.
2.4.5. Interference Study
(i) Interference fromHemoglobin. Interference fromhemoglo-
bin is common in coagulation testing, and hemolytic speci-
men is usually not orminimally affected in latex agglutination
test. The interference study was performed by testing VWF
antibody-latex reagent on plasma pools and plasma pools
spiked at different concentrations of hemolysate. Hemolysate
was prepared by freezing and thawing the whole blood
followed by the osmotic shock protocol [31]. Briefly, normal
sample that was collected in 3.0mLK
2
EDTA tube was
centrifuged at 1,000 g for 10 minutes. Plasma was removed
and replaced with an equal volume of isotonic saline. Cells
were resuspended, and the suspension was centrifuged again
at 1,000 g for 10 minutes. The saline wash was repeated three
times. In the final wash, saline was replaced with distilled
water, and the suspension was stored at −20∘C overnight.
Frozen cells were thawed, mixed, and centrifuged at 2,000 g
for 30 minutes to remove cell debris.
Hemolysate was transferred to a clean tube and hemoglo-
bin level wasmeasuredwith the SysmexXE 5000Hematology
analyzer (Sysmex Corporation, Kobe, Japan). Stock solutions
of hemolysate in normal saline were prepared, and each of
the stock solutions was used to spike plasma pools with high
and low VWF :Ag levels. In the present study, hemolysate
with hemoglobin level of 120 g/L was used to prepare stock
solutions of hemolysate.The hemolysate was diluted 1 : 2, 1 : 4,
1 : 8, 1 : 20, and 1 : 40 with normal saline to obtain the stock
solutions with hemoglobin levels of 60, 30, 15, 6, and 3 g/L,
respectively. One hundred microlitres of each stock solution
were added to 900 𝜇L of plasma pools to obtain plasma pools
with a final hemoglobin level of 6, 3, 1.5, 0.6, and 0.3mg/mL.
(ii) Interference from Rheumatoid Factor. Rheumatoid factor
(RF) is one of the most common interferences in latex-based
methods. It may bind and cross-link antibodies attached to
the latex beads, leading to a false-positive result or falsely
elevated levels of VWF in a sample [32]. The effect of RF on
agglutination reaction was studied by testing VWF antibody-
latex reagent on plasma pools with high and low VWF :Ag
levels. The plasma pools were spiked at different concen-
trations of RF using rheumatoid factor control serum from
MyBioSource, USA (1030 IU/mL).
The RF control serum was diluted 1 : 8, 1 : 7, and 1 : 6 with
high plasma pools to obtain plasma pools spiked with RF
at a concentration of 129, 147, and 172 IU/mL, respectively.
For the preparation of low plasma pools spiked with RF at a
concentration of 10, 15, 52, 103, and 129 IU/mL, the RF control
serum was diluted 1 : 100, 1 : 70, 1 : 20, 1 : 10, and 1 : 8, respec-
tively, with low plasma pools.
2.4.6.MethodComparisonwith the ReferenceMethod.Method
comparison study between latex agglutination test and the
reference method (immunoturbidimetric assay) was con-
ducted by parallel analysis of 132 plasma samples of different
levels of VWF :Ag. The samples were obtained from 40
healthy individuals, 40 patients with cardiovascular diseases,
and 32 patients with other diseases including malignant and
inflammatory disorders. The remaining 20 samples were
cryosupernatant samples (i.e., samples with low levels of
VWF :Ag) that were obtained from Blood Transfusion Ser-
vices. All specimens were tested in ten days, and the testing
was spread over ten months.
Qualitative and semiquantitative latex agglutination tests
were performed using the VWF antibody-latex reagents.
The immunoturbidimetric assay was performed on ACL
Elite Pro Coagulation analyser (Instrumentation Laboratory,
Italy) using Hemosil von Willebrand Factor Antigen kit
from Instrumentation Laboratory, Italy. The procedure for
VWF :Ag by immunoturbidimetric assay was performed
according to the manufacturer’s instructions and adhered to
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Table 2: Estimated concentration of adsorbed antibody in the VWF antibody-latex reagents.
Initial volume of
antibody (𝜇L)
Initial concentration of
antibody (𝜇g)
Concentration of
unadsorbed antibody (𝜇g)
Concentration of
adsorbed antibody (𝜇g)
Percentage of adsorbed
antibody (%)
100 310 192 118 38
150 465 189 276 59
162 502 174 328 65
200 620 184 436 70
226 700 180 520 74
VWF: von Willebrand factor.
the CLSI Document H21-A5 on the specimen collection and
processing of blood specimens for testing the plasma-based
coagulation assays. Normal reference range for VWF :Ag
levels by immunoturbidimetric assay in our laboratory is 50–
150%.
2.5. Statistical Analysis. Statistical analyses were conducted
using the SPSS software version 20 (SPSS Inc., Chicago, IL,
USA). Linear regression analysis was performed to determine
the linearity of the semiquantitative latex agglutination test.
The degree of agreement between qualitative latex aggluti-
nation test and immunoturbidimetric assay was estimated
by calculating the kappa value (𝜅): 0.81–0.99, almost per-
fect agreement; 0.61–0.80, substantial agreement; 0.41–0.60,
moderate agreement; 0.21–0.40, fair agreement; 0.01–0.20,
slight agreement; and <0, less than chance agreement [33].
Spearman’s rho correlation analysiswas used to determine the
degree of relationship between semiquantitative latex agglu-
tination test and immunoturbidimetric assay. The strength
of the relationship is showed by the correlation coefficient
value (𝑟): at least 0.8, very strong; 0.6 up to 0.8, moderately
strong; 0.3 to 0.5, fair; and less than 0.3, poor [34]. Two-
tailed probability (𝑃) value of less than 0.05 was considered
statistically significant.
3. Results
3.1. Preparation of VWF Antibody-Latex Reagent. Table 2
shows the estimated concentration of adsorbed antibody on
the latex beads in the VWF antibody-latex reagents that were
prepared using different concentrations of the VWF anti-
body. The results showed that the concentration of adsorbed
antibody increased as the initial concentration of the VWF
antibody increased. However, the percentage of adsorbed
antibody, that is, 70% and 74%, was not much different when
adsorption method was performed using antibody concen-
tration of 620𝜇g and 700 𝜇g, respectively.
Visual observation on the agglutination reaction showed
that less agglutination was observed from latex beads
adsorbed with less than 400 𝜇g of antibody (i.e., 118 𝜇g,
276𝜇g, and 328 𝜇g) compared to agglutination reaction
from latex beads adsorbed with about 400 𝜇g of antibody.
Agglutination reactions from latex beads coated with 520𝜇g
antibody were slightly more compared to agglutination reac-
tions from latex beads coated with 436 𝜇g antibody (data not
shown). In other words, latex beads with ∼400 𝜇g adsorbed
antibody were sufficient to produce strong agglutination
reaction when mixed with plasma sample. Thus, 200𝜇L of
the VWF antibody with a concentration of 620𝜇g has been
chosen to be the most appropriate concentration for the
adsorption procedure.
Autoagglutination was not seen when VWF antibody-
latex reagent alone was rotated for three minutes. Extending
the time beyond three minutes resulted in reagent drying
that might give false-positive result. No agglutination was
seen when the control reagent (i.e., reagent without adsorbed
antibody) was tested on plasma sample and commercial
controls. Negative reaction was consistently observed when
the VWF antibody-latex reagent was tested on normal saline
and buffers throughout this study.
3.2. Validation Studies. Validation studies were conducted
using VWF antibody-latex reagents that were prepared in
seven batches. The concentration of adsorbed antibody on
the latex beads ranged from 403 to 447 g (i.e., 65–72% from
the initial concentration of the VWF antibody used in the
adsorption procedure) which showed that the percentage of
theVWFantibody adsorbed on the latex beadswas consistent
throughout this study.
3.2.1. Reproducibility and Stability Studies. In the repro-
ducibility study, the end-titre of three samples (i.e., 1 : 32,
1 : 64, and 1 : 128) was consistent when tested three times
within a day. Similarly, the end-titre of two samples (i.e., 1 : 16
and 1 : 128) did not change from day 1 to day 21 (between
days). Testing on the controls showed that the end-titre of low
and normal controls (1 : 4 and 1 : 16, resp.) was reproducible
from day 1 to day 50. In the stability study, VWF antibody-
latex reagent and plasma sample were found to be stable for
qualitative latex agglutination test when stored at 4∘C for at
least 21 days. Semiquantitative test on controls showed that
the VWF antibody-latex reagent was stable for at least 50
days.
All these findings showed that the semiquantitative latex
agglutination test results were reproducible within a day and
between days and the reagent was found to be stable for at
least 50 days when stored at 4∘C. Batch to batch variation was
not detected.
3.2.2. Linearity Study. In the linearity study, a series of known
concentrations of VWF :Ag was established by dilution with
five equally spaced concentrations as shown in Table 3. The
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Table 3: Linearity study on semiquantitative VWF antigen by latex agglutination test.
Tube number Sample 1 Sample 2
VWF :Ag (%)a VWF :Ag (titre)b VWF :Ag (%)a VWF :Ag (titre)b
1 600 1 : 128 460 1 : 64
2 300 1 : 64 230 1 : 32
3 150 1 : 32 115 1 : 16
4 86.9 1 : 16 57.9 1 : 8
5 22.2 1 : 8 27.9 1 : 4
6 9.9 1 : 4 17.6 1 : 2
aVWF : Ag levels (%) measured by immunoturbidimetric assay using Hemosil von Willebrand Factor Antigen kit from Instrumentation Laboratory, Italy.
bVWF : Ag (titre) estimated by using semiquantitative latex agglutination test.
VWF: von Willebrand factor; VWF : Ag: von Willebrand factor antigen.
Table 4: Limit of detection of VWF antigen detected by using latex agglutination test.
Sample/sample number Neat 1 : 2 1 : 4 1 : 8
VWF :Ag (%)a LATe VWF :Ag (%)b LATe VWF :Ag (%)c LATe VWF :Ag (%)d LATe
1 24.2 + 12.1 + 6.1 + 3.0 −
2 20.2 + 10.2 + 5.1 + 2.5 −
3 30.6 + 15.3 + 6.9 + 3.8 −
4 27.6 + 13.8 + 6.9 + 3.4 −
5 26.9 + 13.3 + 6.7 + 3.4 −
6 29.1 + 14.6 + 7.3 + 3.6 −
7 30.3 + 15.2 + 7.6 + 3.8 −
aVWF : Ag levels in neat sample that was measured by immunoturbidimetric assay using Hemosil von Willebrand Factor Antigen kit from Instrumentation
Laboratory, Italy.
b,c,dEstimated VWF :Ag levels in 1 : 2, 1 : 4, and 1 : 8 diluted samples (i.e., by dividing the VWF :Ag levels of neat sample by the dilution factors of 2, 4, and 8,
respectively.
ePositive (+) and negative (−) reactions observed when neat and diluted samples were tested by using latex agglutination test.
VWF : Ag: von Willebrand factor antigen; LAT: latex agglutination test.
table shows the latex agglutination test results (titre) and the
levels of VWF :Ag in undiluted (tube 1) and diluted samples
(tubes 2–6). It was shown in the table that the semiquanti-
tative latex agglutination test results (titre) were directly pro-
portional to the levels of VWF :Ag in the plasma sample. Lin-
earity of the semiquantitative VWF :Ag latex agglutination
test was demonstrated in sample 1 (𝑟2 = 0.9985) and sample 2
(𝑟2 = 0.9999). A regression line that was fit to the points
was observed in both samples (graphs not shown). The
linearity was also demonstrated at the titre ranging from 1 : 2
to 1 : 128 when the results of both samples were combined and
analyzed (𝑟2 = 0.9361). All these findings have demonstrated
a linear relationship between the observed results (VWF :Ag
titre) and the true concentrations of VWF :Ag in the plasma
samples.
3.2.3. Determination of Limit of Detection. In the limit of
detection study, plasma samples with low levels of VWF :Ag
(in the range of 20.2% to 30.6%) were obtained from seven
cryosupernatant samples (Table 4). Table 4 shows the agglu-
tination reaction observed when latex agglutination test was
performed on undiluted (neat) samples and diluted samples
(at 1 : 2, 1 : 4, and 1 : 8 dilutions). As shown in the table, the
lowest level of VWF :Ag that still showed positive reaction is
5.1% (sample number 2 at 1 : 4 dilution), and the highest level
of VWF :Ag that showed negative reaction is 3.8% (sample
number 7 at 1 : 8 dilution). These results showed that the
lowest level of VWF :Ag that the latex agglutination test can
detect to determine the presence (positive result) or absence
(negative result) of VWF :Ag was 5.1%. Thus, the limit of
detection of VWF :Ag by latex agglutination test is approx-
imately 5%. Besides that, reproducibility of the agglutination
reaction at VWF :Ag levels of 5.1 and 3.8% was also checked
by testing six times the diluted samples of number 2 (at 1 : 4
dilution) and number 7 (at 1 : 8 dilution), respectively. Sample
number 2 showed positive reactions in all six replicates, while
sample number 7 showed negative reaction in all six repli-
cates. These findings showed that the latex agglutination test
reliably produced consistent results near the cutoff concen-
tration.
3.2.4. Interference Study. Visible agglutinationwas seenwhen
latex agglutination test was performed on undiluted plasma
pools and undiluted plasma pools with a final hemoglobin
level of 0.3, 0.6, 1.5, 3, 6, and 12mg/mL. The end-titre of
1 : 32 was obtained when semiquantitative latex agglutination
test was performed on high plasma pool. The same end-titre
(1 : 32) was observed when the test was performed on high
plasma pools with hemoglobin level of 0.3, 0.6, 1.5, 3, 6, and
12mg/mL. Similarly, the end-titre of low plasma pools with
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Table 5: Rheumatoid factor interference on high and low plasma pools.
Type of the plasma pool Vol. of RF control serum(𝜇L)a
Vol. of the plasma pool
(𝜇L)
RF conc. in plasma pool
(IU/mL) vWF LAT (titre)
High plasma pool
25 175 129 1 : 64
30 180 147 1 : 128 (weak)
40 200 172 1 : 128
Low plasma pool
10 990 10 1 : 2
10 390 26 1 : 4
10 190 52 1 : 8
10 90 103 1 : 16
10 70 129 1 : 32
aRheumatoid factor control serum fromMyBioSource, USA (1030 IU/mL), was used to spike plasma pools.
RF: rheumatoid factor; VWF LAT: von Willebrand factor latex agglutination test; vol., volume; conc., concentration.
Table 6: Crosstabulation of VWF antigen levels and qualitative VWF by latex agglutination test results.
Qualitative VWF latex agglutination test (LAT score) Total
1+ 2+ 3+ 4+
VWF :Ag levels by immunoturbidimetric assay (%)
<20 6 1 0 0 7
20–50 0 12 0 0 12
50–150 0 1 46 2 49
>150 0 0 15 49 64
Total 6 14 61 51 132
VWF: von Willebrand factor; VWF : Ag, von Willebrand factor antigen; LAT: latex agglutination test.
hemoglobin level of 0.3, 0.6, 1.5, 3, 6, and 12mg/mL was the
same as the end-titre of low plasma pool without hemoglobin
interference (1 : 4). These results showed that hemoglobin
did not cause interference in latex agglutination test and
semiquantitative test result was not affected by hemoglobin
level up to 12mg/mL.
Table 5 shows the end-titre of high and low plasma pools
spiked at different concentrations of RF. As shown in the
table, interference fromRF on latex agglutination test was not
detected in high plasma pools spiked with RF at concentra-
tions up to 129 IU/mL.Nevertheless, the interference fromRF
was observed in low plasma pools spiked with RF at concen-
trations of 26, 52, 103, and 129 IU/mL. The end-titre of high
and low plasma pools without interference from RF was 1 : 64
and 1 : 2, respectively.These results showed that RF interfered
with the latex agglutination test result when the test was
performed on the plasma sample containing low levels of
VWF :Ag and high levels of RF (>26 IU/mL). However, latex
agglutination test result of plasma sample containing high
levels of VWF :Ag was not affected by RF at concentrations
of <130 IU/mL.
3.2.5. Method Comparison with the Reference Method. Com-
parison study between qualitative latex agglutination test
and immunoturbidimetric assay showed a kappa value of
0.77 which indicates a substantial agreement between the
two tests. Table 6 shows the crosstabulation of 132 samples
included in this study. Semiquantitative latex agglutination
test was strongly correlated with immunoturbidimetric assay
(Spearman’s rho, 𝑟 = 0.946, 𝑃 < 0.001) across a range of
VWF :Ag levels from 34.5% to 870%.
Based on the results from kappa statistic and correlation
study, the scoring system for agglutination reactions and cor-
relation with the VWF :Ag levels (using immunoturbidimet-
ric assay) is shown in Table 7. The proposed interpretation
guide is also put in a footnote.
4. Discussion
To the best of our knowledge, there has been no reported
study or technical description available on the rapid test for
VWF :Ag utilising latex agglutination method. At present,
the application of this method has not been used in clin-
ical practice for monitoring of patients with low and high
plasma levels of VWF :Ag. Screening of VWDpatients before
confirmation tests and monitoring of patients at high risk of
thrombotic event in the area with low-resource settings or at
the bedside can be performed if rapid test for VWF :Ag is
available. Hence, there is a need to develop a rapid and simple
latex agglutination test that can reliably detect and estimate
VWF :Ag in the plasma sample.
Latex agglutination test is based on the observation of
visible clumps that are formed from the reaction of antigen-
antibody complexes. The antigen-antibody complexes can be
prepared by passive adsorption or covalent coupling method.
In the early stage of the present study, attempts had beenmade
to couple VWF antibody with the carboxylated latex beads
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Table 7: Correlation of result interpretations by latex agglutination test and immunoturbidimetric assay.
Qualitative latex agglutination test (LAT
score)
Semiquantitative latex agglutination test
(titre)
VWF :Ag levels by immunoturbidimetric
assay (%)
1+ 1 : 2 <20
2+ 1 : 4, 1 : 8 20–50
3+ 1 : 16, 1 : 32 50–150
4+ ≥64 >150
The proposed interpretation guide: normal level of VWF :Ag is indicated by LAT scores of 2+ and 3+ or titres from 1 : 8 to 1 : 32. Abnormal low VWF :Ag is
indicated by LAT scores of 0, 1+, and 2+ or titres of 1 : 2 and 1 : 4. Abnormal high VWF :Ag is indicated by LAT score of 4+ or titres of ≥64.
LAT: latex agglutination test; VWF : Ag: von Willebrand factor antigen.
by covalent coupling method. The coupling procedure was
performed in MES buffer at pH 6.0 according to the protocol
from themanufacturer. Unfortunately, there was no antibody
coated on the latex beads (data not shown). However, the
VWF antibody was successfully adsorbed onto the surface
of chloromethyl latex beads by passive adsorption method.
These findings were similar to the reported study by Garcia et
al., 2015 [35]. In the present study, amaximal physical adsorp-
tion of the VWF antibody onto chloromethyl latex beads was
obtained at pH 7.4, a pH that is close to the isoelectric point
of polyclonal immunoglobulin (IgG) antibody [36, 37].
Interference by RF in the latex agglutination test for the
detection of VWF :Ag was expected. RF is known to cause
analytical error in automated immunoturbidimetry assay that
presented the main limitation of this method. Despite this
limitation, the findings do nevertheless show that the effect of
the interference was less prominent in the sample with high
levels of VWF :Ag compared to the sample with low levels
of VWF :Ag. The expected interference is without any doubt
due to the usage of whole IgG in the passive adsorption
method. It iswell known that rheumatoid factor can bindwith
the Fc region of IgG, causing false agglutination thatmay alter
the result of the test. In the literature, the usage of antibody
fragments such as Fab or F(ab󸀠)
2
was recommended to elim-
inate the interference from rheumatoid factor [37]. Antibody
fragment is suggested in future study, and optimization is
required as the antibody fragment is more acidic than the
polyclonal antibody.
In the present study, the agglutination observed from the
reaction between VWF antibody-latex reagent and positive
sample may not be optimum as expected. Experiments using
higher initial concentration of VWF antibody with a more
intensive procedure to ensure maximal bead coating could
be performed in the future study. Not only that, but the
orientation of adsorbed antibody could also be studied to
ensure a proper alignment of antibody on latex beads. Clarizia
et al., 2009 [38], have demonstrated a method for detecting
the aligned andmisaligned antibodies on the surface on latex
beads. Due to some technical constraint, maximal bead coat-
ing cannot be ensured, and a study on orientation of adsorbed
antibody could not be performed. Another limitation of this
study is that the size of the clumping was only estimated
by visual observation. In future study, it is recommended
to measure the clumping or macroscopic clusters using
microscope or other methods.
There is a potential clinical application of this rapid latex
agglutination test as a routine test in various premises includ-
ing small laboratory and clinic and at the bedside.The clinical
aspect of low levels of VWF :Ag is well recognized, but not
many medical personnel realized the implications of high
VWF :Ag levels in medical practice. An inherited bleeding
disorder known as von Willebrand disease (VWD) is asso-
ciated with an abnormality in VWF, and type 1 VWD is the
commonest form that is associated with low VWF :Ag [39].
On the other hand, high levels of VWF :Ag are associated
with thrombotic risks and had been extensively studied in
many medical conditions particularly coronary heart disease
(CHD) and stroke. It has been shown that CHD patients with
high baseline of VWF :Ag levels are at risk of acute vascular
events related to thrombosis [40]. The current clinical guide-
lines do not incorporate the measurement of VWF :Ag in
the routine assessment of CHD patients but, from various
studies, there is a role in monitoring the levels of VWF :Ag.
Detection of persistent high levels or increasing trends of
VWF :Ag levels would alert the treating doctor for certain
clinical measures to improve the patient care.
Latex agglutination test for the detection of VWF :Agwas
found to be simple to perform, and the results can be obtained
within three minutes, making it suitable to be used in areas
with limited laboratory facilities. The result obtained by
the latex agglutination test is reliable as shown by the findings
from reproducibility, stability, linearity, limit of detection,
and method comparison studies. Prozone effect was not
detected at VWF :Ag levels up to 870%. The stability of the
reagents used for this method was up to 50 days and in this
study no stabilizer or preservatives were used. The plasma
for VWF :Ag estimation was stable for up to 21 days which
may be related to the protein structure; however, more tests
are needed to confirm the suitable plasma storage recom-
mendation for this method. All these findings showed the
usefulness of this method in detecting and estimating high
and low levels of VWF :Ag.This method might be useful in
the monitoring of VWF :Ag in patients that are at a high risk
of vascular event related to endothelial dysfunction. Similarly,
this method could be used to estimate VWF :Ag levels in
patients with VWD before confirmation with standard test
panels in the specialized coagulation laboratory.
However, we only evaluate the latex agglutination test
in quantitative terms by using plasma samples containing
low and high levels of VWF :Ag. This application mainly
addressed the VWD type 1 which is more common in clinical
Journal of Immunology Research 9
practice. In future study, plasma samples with qualitative
VWF abnormalities (e.g., type II VWD or acquired VWD
patients demonstrating abnormal VWF function with vari-
ables VWF :Ag levels) could be included in the comparison
study to confirm the application of the latex agglutination test
for assessing VWF :Ag levels in various clinical situations. In
summary, this test method needs to be refined and compared
with other latex agglutination tests available in the market
before it is used on patient samples.
5. Conclusion
Latex agglutination test for VWF :Ag is simple, rapid, and
reproducible, correlates well with the reference method, and
is suitable to be used in areaswith limited laboratory facilities.
The test has commercial potential as a low-cost alternative
method for the detection and estimation of low levels and
high levels of VWF :Ag that could help in themanagement of
VWDtype 1 patients andpatients at risk of thrombotic events,
respectively. However, the testmay not be suitable for patients
with a high level of rheumatoid factor.
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